GNBT 1.68 Generex Biotechnology Corporation Announces Prestigious National Award Received by Clinical Investigator Who Has Done Extensive Work On Generex Oral-lyn
Jul 24, 2007 8:47:00 AM
2007 PrimeNewswire, Inc.
WORCESTER, Mass., July 24, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Dr. Jaime Guevara-Aguirre was recently awarded the Vicente Rocafuerte Award for Scientific Merit. The top honor was granted to Dr. Guevara-Aguirre by the National Congress of Ecuador.
The determining factors, according to the Medical and Scientific Commission of the National Congress of Ecuador, were Dr. Guevara-Aguirre's research and clinical work in Generex Oral-lyn(tm) and Laron syndrome.
Dr. Jaime Guevara was the first clinician to conduct human clinical trials on Generex Oral-lyn(tm) back in 1995 and since then had conducted numerous trials of Generex Oral-lyn(tm) with both Type 1 and Type 2 patients. Some of his trials assisted in establishing the dosing regiment for Generex Oral-lyn(tm) which have been incorporated in the company's Phase III protocol for global trials.
"We are pleased that a clinician who has devoted much clinical work towards Generex Oral-lyn(tm) was bestowed with the highest medical and scientific honour of his country," says Anna Gluskin, Generex's President and CEO. "The fact that Dr. Jaime Guevara-Aguirre was recognized specifically for his work towards Generex Oral-lyn(tm) signifies that governmental bodies and agencies are starting to recognize the importance that Generex Oral-lyn(tm) will play in the treatment of diabetes."
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and before the end of 2007 the Company expects to begin Phase 3 trials of the product in the United States, Canada and Europe. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: Generex Biotechnology Corporation
Shayne Gilliatt
800-391-6755 or 416-364-2551
CEOcast, Inc.
Andrew Hellman
212-732-4300
News 
Market Data 
Discover 
